Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren\'s Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.
Epistemonikos ID: 99b08ed1090cc9162cdae9bf61c19d3662255e9f
First added on: Aug 27, 2026